Biosimulation Market to Hit USD 9.18 Billion by 2029 with 16.7% CAGR | MarketsandMarkets™. [Yahoo! Finance]
Simulations Plus, Inc. (SLP)
Last simulations plus, inc. earnings: 4/9 04:35 pm
Check Earnings Report
US:NASDAQ Investor Relations:
simulations-plus.com/software/overview
Company Research
Source: Yahoo! Finance
USD 9.18 billion by 2029, driven by a CAGR of 16.7% from 2024 to 2029. The major factors driving the growth of the biosimulation market include the high rate of clinical trial failures, the growing necessity of being able to predict drug pharmacokinetics and pharmacodynamics, as well as toxicity management. According to a research article published by the National Library of Medicine in February 2022, the drug discovery and development process takes about 10-15 years for a new drug to be approved for clinical use. And 90% of the drug candidates fail during the phases I, II, and III of clinical trials and drug approvals. The possible reasons stated for the failure include lack of clinical efficacy, unmanageable toxicity, poor drug-like properties, lack of commercial needs, and poor strategic planning. The use of biosimulation helps address these challenges to increase the chances of drug approval and facilitate swift trial processes. Download PDF Brochure: https://www.marketsandmarke
Show less
Read more
Impact Snapshot
Event Time:
SLP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLP alerts
High impacting Simulations Plus, Inc. news events
Weekly update
A roundup of the hottest topics
SLP
News
- Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar? [Yahoo! Finance]Yahoo! Finance
- Simulations Plus to Participate in the BTIG Digital Health ForumBusiness Wire
- Simulations Plus, Inc. (NASDAQ: SLP) was upgraded by analysts at Stephens to a "strong-buy" rating.MarketBeat
- Simulations Plus, Inc. (NASDAQ: SLP) is now covered by analysts at Stephens. They set an "overweight" rating and a $39.00 price target on the stock.MarketBeat
- Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting InjectablesBusiness Wire
SLP
Earnings
- 10/23/24 - Beat
SLP
Sec Filings
- 11/5/24 - Form 4
- 11/5/24 - Form 4
- 11/5/24 - Form 4
- SLP's page on the SEC website